

Discover Life Science Canada

by JETRO Canada and Shonan iPark



#1 Toronto EcoSystem

日時 日本時間
9am - 10am on 8/7 (Friday)

EST
8pm - 9pm on 8/6 (Thursday)

会場 Web EX



Meeting number (access code)

131 055 9038

Meeting password

iParkevent123@

<https://onetakeda.webex.com/onetakeda/j.php?MTID=m66cf19a4098017c613a0b8e94c9c360c>

Agenda

1. Opening Remarks

- Toshio Fujimoto, General Manager, Shonan iPark
- SAKAI Takuji, Executive Director, JETRO Toronto

2. Overview of Ontario Life Sciences Ecosystem

Ontario Government

3. Startup Pitch

Cyclica / Ovensa / Lumasonix

4. Q&A

MC

- Tyson Garbe, Associate Director, JETRO Toronto
- Yuri Ogiso, Commercial and Business Development, Shonan iPark

Overview of Ontario Life Sciences Ecosystem



Ontario Government

Presenter

Jenny Ge

Senior Sector Adviser
MEDJCT's Industry and Sector
Strategy Division
(Life Sciences team)



As Canada's most populous province, a driver of national economic growth and the location of both Canada's capital city and largest city, Ontario is the headquarter for a large number of multinational corporations and innovative home-grown companies. Ontario is home to a thriving and comprehensive life sciences ecosystem, comprised of the pharmaceutical industry, the medical device industry and a thriving biotechnology industry in regenerative medicine and cell therapy. The numerous benefits of investing and being located in Ontario will be discussed, such as government incentive programs, top research organizations and Ontario's strengths in cutting edge technologies such as artificial intelligence (AI).

Startup Pitch



Cyclica Inc.



Presenter

Naheed Kurji

Co-Founder, President & CEO



Cyclica is the first company to approach polypharmacology with a structure-based, AI-augmented in silico discovery platform, centered on Ligand Design and Ligand Express. Powered by MatchMaker™, a proprietary deep learning proteome screening technology, and POEM™, an innovative supervised learning technology for predicting molecular properties, Cyclica's platform is suited uniquely to the design of novel, chemical matter by simultaneously prioritizing compounds based on their on- and off-target polypharmacological profiles as well as their developmental properties. With a world-class team that has deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs.

<https://www.cyclicarx.com/>
<https://www.cyclicarx.com/science>



Ovensa Inc.



Presenter

Stéphane Gagné

President & CEO



Ovensa Inc. is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines. Ovensa leverages the cationic charges on its patented biopolymer called TRIOZAN™, to cross the skin, the mucosae or the blood-brain barrier in order to deliver the therapeutic molecule to the targeted tissue or cell.

<https://ovensa.com/>



Lumasonix Inc.



Presenter

Morris Smith

VP Partnerships and Product



Lumasonix is a 2020 Bio International Convention Startup finalist transforming cancer care through early detection. We are developing the first general cancer screening through the detection of circulating tumor cells (CTC's) in blood. Tumors shed CTCs in blood as they grow, and through Photo-acoustic and Ultrasound imaging, we detect their physical characteristics, classify and count the CTCs. This process will be fully automated to annually screen a national population with a low-cost test.

<http://www.lumasonix.com/>